Literature DB >> 86314

Immunochemical, serologic, and immunologic properties of major antigens isolated from the Legionnaires' disease bacterium. Observations bearing on the feasibility of a vaccine.

K H Wong, W O Schalla, R J Arko, J C Bullard, J C Feeley.   

Abstract

Two antigens were isolated from each of three strains of the Legionnaires' disease (LD) bacterium. One antigen was serotype-specific; the other cross-reacted with strains of LD bacteria of different serotypes. The serotypic antigens contained all the major branched-chain fatty acids characteristic of LD bacteria and were a lipid-protein-carbohydrate complex. Electrophoresis resolved the serotypic antigen of Knoxville 1 strain into four protein bands and one glycoprotein band with molecular weights ranging from 0.5 to 7.2 x 10(5). The specificity of the serotypic antigens was established by immunofluorescent staining, and double gel diffusion confirmed the absence of cross-reactions between the serotypic antigens of different types and the partial identity of the serotypic antigens from serologically related strains. The cross-reacting antigens formed precipitin bands with all the homologous and heterologous sera tested. Induction of immunity by vaccination with serotypic antigens was shown in three animal models using guinea pigs and mice. Passive-transfer of immunity (IgG) was also shown in mice and guinea pigs. These observations raise the possiblity of a vaccine for protection against infection of LD bacteria.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86314     DOI: 10.7326/0003-4819-90-4-634

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  29 in total

1.  Serospecificity and opsonic activity of antisera to Legionella pneumophila.

Authors:  W Johnson; E Pesanti; J Elliott
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Antigenic specificity of the antibody response in humans during legionellosis.

Authors:  A Brown; M W Lema; M S Brown-Schlumpf
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

3.  Measure of immunoglobulin G-, M-, and A-specific titers against Legionella pneumophila and inhibition of titers against nonspecific, gram-negative bacterial antigens in the indirect immunofluorescence test for legionellosis.

Authors:  H W Wilkinson; C E Farshy; B J Fikes; D D Cruce; L P Yealy
Journal:  J Clin Microbiol       Date:  1979-11       Impact factor: 5.948

4.  Legionella pneumophila surface antigens cloned and expressed in Escherichia coli are translocated to the host cell surface and interact with specific anti-Legionella antibodies.

Authors:  N C Engleberg; E Pearlman; B I Eisenstein
Journal:  J Bacteriol       Date:  1984-10       Impact factor: 3.490

5.  Immune defenses against Legionella pneumophila in rats.

Authors:  B Rolstad; B P Berdal
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

6.  Cloning and expression of Legionella pneumophila antigens in Escherichia coli.

Authors:  N C Engleberg; D J Drutz; B I Eisenstein
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

7.  Simple, transparent medium for study of legionellae.

Authors:  S R Johnson; W O Schalla; K H Wong; G H Perkins
Journal:  J Clin Microbiol       Date:  1982-02       Impact factor: 5.948

8.  Electrophoretic characterization of soluble protein extracts of Legionella pneumophila and other members of the family Legionellaceae.

Authors:  M Lema; A Brown
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

9.  Hybridoma-derived monoclonal immunoglobulin M antibodies to Legionella pneumophila serogroup 1 with diagnostic potential.

Authors:  K K Sethi; V Drüeke; H Brandis
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

10.  Plasmid and surface antigen markers of endemic and epidemic Legionella pneumophila strains.

Authors:  A Brown; R M Vickers; E M Elder; M Lema; G M Garrity
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.